Natixis Advisors, L.P. Vaxcyte, Inc. Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
A detailed history of Natixis Advisors, L.P. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 22,697 shares of PCVX stock, worth $2.09 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
22,697
Previous 14,091
61.07%
Holding current value
$2.09 Million
Previous $1.06 Million
143.8%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding PCVX
# of Institutions
358Shares Held
123MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$1.05 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$1.01 Billion0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$916 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$801 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$451 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.46B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...